Avalo Therapeutics AVTX
NASDAQ AVTX
$8.51 +1.35 (+18.78%)
As of: Nov 11, 2026 · 3:59 PM EST

Avalo Therapeutics (AVTX) EV to EBITDA (2017 - 2018)

Updated

Avalo Therapeutics' (AVTX) EV to EBITDA was 13.47 for Q2 2018, up 37.2% from the prior quarter.

Analysis

Avalo Therapeutics (AVTX) EV to EBITDA (2017 - 2018) Analysis & Trends

Over the twelve months ended Jun 30, 2018, Avalo Therapeutics' EV to EBITDA came in at 10.76; for FY2017, it came in at 10.23.

  • Per Business Quant data, the three quarters before Q2 2018 came in at 9.82 (Q1 2018), 10.23 (Q4 2017) and 1.48 (Q3 2017).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Avalo Therapeutics 386.09 Mn -587.48 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2018 3,278.84
Mar 31, 2018 2,399.32
Dec 31, 2017 2,495.79
Sep 30, 2017 700.31
API Access

Avalo Therapeutics EV to EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=AVTX&period=max&api_key=YOUR_API_KEY